Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2011, Article ID 769890, 3 pages
Clinical Study

Mannan-Binding Lectin Levels and Activity Are Not Altered in Atopic Dermatitis Patients with a History of Eczema Herpeticum

1Division of Allergy, Immunology, Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
2Department of Dermatology, Johns Hopkins University, Baltimore, MD 21205, USA
3Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, 80539 Munich, Germany
4Department of Dermatology, University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 697, Rochester, NY 14642, USA

Received 18 July 2011; Accepted 23 August 2011

Academic Editor: Elizabeth Helen Kemp

Copyright © 2011 Kemp W. Bundy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Eczema herpeticum (EH) is a potentially serious, systemic complication in subjects with atopic dermatitis (AD) caused by herpes simplex virus (HSV). The innate immune dysregulation that predisposes these subjects to cutaneous viral infections is not well understood. We tested the hypothesis that defects in mannan-binding lectin (MBL) may be associated with an increased risk of EH. Methods. We evaluated serum MBL levels and functional activity in 13 AD subjects with a history of EH (EH+) and 21 AD subjects with no history of EH (EH−). MBL levels were detected by enzyme immunoassay. MBL pathway functional activity was evaluated by determining MBL C4b deposition capacity. Results. We found no statistical difference in MBL serum levels or function between EH+ and EH− groups. Conclusion. Considering the limitations of this study (e.g., small samples size) our findings suggest that MBL defects do not play a role in EH.